Isn't it strange, two FDA-approved drugs - topical ruxolitinib or tofacitinib - can reawaken dormant hair follicles! According to the study, within 3 weeks, mice that received topical ruxolitinib or tofacitinib had regrown nearly all their hair (right photo; drug was applied only to the right side of the mouse). Little to no hair growth occurred in control mice during the same timeframe (left photo). According to researchers at Columbia University Medical Center, inhibiting a family of enzymes inside hair follicles that are suspended in a resting state restores hair growth.
These drugs, known as JAK inhibitors have been approved to treat blood diseases (ruxolitinib) and the other for rheumatoid arthritis (tofacitinib). Both are being tested in clinical trials for the treatment of plaque psoriasis and alopecia areata, an autoimmune disease that causes hair loss.
